Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937986 · ClinicalTrials.gov registry record · Early Phase 1
Suvorexant and Cocaine
A Early Phase 1 study, sponsored by William Stoops.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03937986 is a Early Phase 1 study that has completed, run by William Stoops. The registered enrollment target is 8 participants.
The verdict
NCT03937986, a Early Phase 1 study, has completed, sponsored by William Stoops.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The research proposed here will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for cocaine, as well as other cocaine-associated maladaptive behaviors in active cocaine users. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of cocaine in humans. As such the outcomes will contribute to our understanding of the clinical neurobiology of cocaine use disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on cocaine addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.
Interventions
- DRUG Placebo oral capsule
- DRUG Suvorexant
- DRUG Cocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2022-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03937986
The ClinicalTrials.gov registry entry for NCT03937986 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is William Stoops, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03937986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03937986 about?
NCT03937986 is a clinical study titled "Suvorexant and Cocaine". The research proposed here will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for cocaine, as well as other cocaine-associated maladaptive behaviors in active cocaine users. This study will also provide basic science ...
What is the current status of trial NCT03937986?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2019-07-11. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT03937986?
The interventions under investigation include: Placebo oral capsule (DRUG), Suvorexant (DRUG), Cocaine (DRUG).
Who is sponsoring clinical trial NCT03937986?
This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.